FourWorld Capital Management »

Cytokinetics shares owned by FourWorld Capital Management

Quarter-by-quarter ownership of Cytokinetics (CYTK) shares owned by FourWorld Capital Management from 13F filings

Historical chart of FourWorld Capital Management investment in Cytokinetics

Tip: Access up to 7 years of quarterly data

All positions including Cytokinetics held by FourWorld Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Cytokinetics by FourWorld Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $14M 170k 83.49

More positions owned by FourWorld Capital Management

Spdr S&p 500 Etf Tr Tr Unit Call Option (SPY)
Semper Paratus Acquisition C Unit 11/04/2026
Semper Paratus Acquisition C *w Exp 11/04/202
Seritage Growth Pptys Cl A (SRG)
Cytokinetics Com New Call Option (CYTK)
Odyssey Marine Expl Com New (OMEX)
Bristol-myers Squibb Right 12/30/2030 (CELG.R)
Albertsons Cos Common Stock (ACI)
Arbutus Biopharma (ABUS)
Evolus (EOLS)
Solid Power Class A Com (SLDP)
iRobot Corporation (IRBT)
Alibaba Group Hldg Sponsored Ads Call Option (BABA)
Pilgrim's Pride Corporation (PPC)
Hollysys Automation Tchngy L SHS (HOLI)

View all positions for FourWorld Capital Management

Top funds holding Cytokinetics

Vanguard Group
Wellington Management Company
Caption Management
T. Rowe Price Associates
Henderson Group
Boxer Capital
Citadel Advisors
Partner Fund Management
Logos Global Management
Lord, Abbett & Co
Millennium Management
Artal Group
Barclays
Gts Securities
Goldman Sachs Group

View all funds holding Cytokinetics